CASI Pharmaceuticals (CASIF) Other Non Operating Income (2022 - 2025)

CASI Pharmaceuticals has reported Other Non Operating Income for 4 years, with the latest figure at -$3.2 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non Operating Income fell 2109.55% year-over-year to -$3.2 million; the trailing twelve-month figure through Dec 2025 stood at -$4.1 million (down 2060.94% YoY), and the FY2025 full-year result was -$2.2 million, down 1025.52% from the prior year.
• Other Non Operating Income for Q4 2025 stood at -$3.2 million, down from -$433000.0 in the prior quarter.
• The five-year high for Other Non Operating Income was $5.6 million in Q4 2022, with the low at -$3.2 million in Q4 2025.
• Historically, Other Non Operating Income has averaged $23062.5 across 4 years, with a median of -$194000.0 in 2023.
• Annual changes were most pronounced in 2024 — Other Non Operating Income soared 502.27% — and 2025, when it tumbled 2109.55%.
• CASI Pharmaceuticals' Other Non Operating Income stood at $5.6 million in 2022, then sank by 70.59% to $1.6 million in 2023, then slumped by 90.41% to $157000.0 in 2024, then plunged by 2109.55% to -$3.2 million in 2025.
• The last three Other Non Operating Income figures came in at -$3.2 million (Q4 2025), -$433000.0 (Q3 2025), and -$415000.0 (Q2 2025), per Business Quant data.